Boston Common Asset Management LLC Has $15.54 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Boston Common Asset Management LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,818 shares of the biopharmaceutical company's stock after selling 7,258 shares during the period. Boston Common Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $15,542,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of REGN. Avanza Fonder AB bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $7,414,000. Fermata Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $207,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 3,106 shares of the biopharmaceutical company's stock worth $2,212,000 after purchasing an additional 99 shares during the period. Outlook Wealth Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $305,000. Finally, Park Avenue Securities LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 6.9% during the 4th quarter. Park Avenue Securities LLC now owns 2,019 shares of the biopharmaceutical company's stock valued at $1,438,000 after purchasing an additional 130 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a report on Thursday, October 24th. Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a report on Friday, November 1st. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Finally, Morgan Stanley dropped their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $11.65 during mid-day trading on Friday, hitting $681.58. 1,107,622 shares of the company were exchanged, compared to its average volume of 678,713. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20. The business has a 50 day simple moving average of $738.60 and a 200-day simple moving average of $949.99. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $74.90 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.